Site Menu
Search Close Search
Search Close Search
Page Menu

Access to the PubMed list of publications

Total: displaying 15 out of 50 results

  • Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities

    Monday, June 01, 2026
    Author(s): Cornelia Laule,Julien Cohen-Adad,Atlee A Witt,Gabriele C De Luca,Cristina Granziera,B Mark Keegan,Anne Kerbrat,Eric C Klawiter,Shannon Kolind,Kristin P O'Grady,Jiwon Oh,Kurt G Schilling,Dinesh K Sivakolundu,Seth A Smith,Ceren Tozlu,Irene M Vavasour,Francesca Bagnato,Susan A Gauthier,Caterina Mainero,Eva Alonso-Ortiz,Rohit Bakshi,Erin S Beck,Matthew R Brier,Christopher C Hemond,Stephen Krieger,David Kb Li,Russell T Shinohara,Roland G Henry,North American Imaging in Multiple Sclerosis (NAIMS) Cooperative
    Source: Multiple sclerosis (Houndmills, Basingstoke, England)
    The spinal cord plays a central role in the pathophysiology and clinical manifestations of multiple sclerosis (MS), yet remains under-studied compared with the brain. This review summarizes key insights from the 2025 North American Imaging in MS Spinal Cord Imaging Workshop, highlighting recent advances, ongoing challenges, and future opportunities in MS spinal cord imaging. We review pathological studies and outline the clinical relevance of spinal cord lesions and atrophy for diagnosis,...

  • Global transcriptional changes across multiple isogenic C9orf72 patient iPSC-derived neurons

    Monday, June 01, 2026
    Author(s): Aparna Sreeram,Desiree M Baron,Alberto Brusati,Karly Stallworth,Jack Humphrey,John E Landers
    Source: iScience
    Hexanucleotide repeat expansions in C9orf72 are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD); yet, mechanisms underlying selective neuronal vulnerability remain unclear. A major challenge in identifying consistent transcriptomic changes across C9orf72 patient-derived neuron lines has been heterogeneous differentiations, lack of isogenic controls and low sequencing depth. To overcome these challenges, we generated homogeneous cortical...

  • Outcomes in checkpoint inhibitor induced neuromuscular immune related adverse events: A case series

    Monday, May 25, 2026
    Author(s): James Lanni,Abigail Bose,David Cachia
    Source: Journal of neuroimmunology
    Immune-checkpoint inhibitors, a mainstay of treatment of solid tumors, rarely lead to activation of the host immune system against another target, causing autoimmune inflammation of other end organs known as immune-related adverse events (ir-AEs). When ir-AEs are directed at the neuromuscular system, clinical consequences include myositis and myasthenic syndromes. In this article, we describe three cases presenting with neuromuscular ir-AEs. Two patients had lung adenocarcinoma and were treated...

  • Multifrequency Electrical Impedance Myography Enhanced with Machine Learning for Screening Patients with Neuromuscular Disorders

    Friday, May 22, 2026
    Author(s): Buket Sonbas-Cobb,Seward B Rutkove,Baoguo Wei,Sara Robicheau,W David Arnold,Kaneshia Hives,Amy Bartlett,Peter Riley,Aleah Pagan,Stephen M Chrzanowski,Basil T Darras,Stephen J Kolb
    Source: Annals of biomedical engineering
    We evaluated surface electrical impedance myography (EIM) enhanced with machine learning to serve as a new office-based screening tool for neuromuscular disease METHODS: EIM of nine muscles was successfully performed in 119 adults and 111 children (approximately half healthy and half diseased) for a total of 3158 individual muscle measurements. Multifrequency data were processed with feature engineering and classification. Nested cross-validation assessed performance, with muscle-based...

  • Ontogeny and Natural History of Therapy-Related Clonal Hematopoiesis From a Multidisciplinary CHIP Clinic

    Wednesday, May 20, 2026
    Author(s): Shyam A Patel,Valerie Zhu,William K Gerber,Sakiko Suzuki,Charlotte Barker,Lloyd Hutchinson,Salwa Khedr,David Cachia,Abhishek A Mangaonkar,Matthew E McGuiness,Anne W Higgins,Patricia M Miron,Jonathan M Gerber
    Source: American journal of hematology
    Age-related changes in human hematopoietic stem cells (HSCs) often form the basis for clonal hematopoiesis (CH), which presages the development of overt myeloid neoplasm with variable risk. CH can also arise after exposure to chemotherapy, radiotherapy, or immune interventions. In this study, we performed clinico-genomic profiling of therapy-related CH (t-CH) (n = 67) versus de novo CH (n = 123) from a multidisciplinary CHIP Clinic. The most enriched mutations in t-CH were TET2 (26.2%), DNMT3A...

  • Possible Diagnostic Error in Cervical Artery Dissection: Analysis of STOP-CAD Study

    Thursday, May 14, 2026
    Author(s): Ekaterina Bakradze,Liqi Shu,Shadi Yaghi,Thanh Lam Ngoc Tran,Ross Curtiss Crandal,Evan Lester,Daniel M Mandel,James Ernest Siegler,Mary Penckofer,Ava Leigh Liberman,Thalia S Field,Farhan Khan,Wayneho Kam,Brian Mac Grory,Faddi G Saleh Velez,Nils Henninger,Cheran Elangovan,Balaji Krishnaiah,Preet Gandhi,Reza Bavarsad Shahripour,Malik Ghannam,Mirjam Rachel Heldner,Kateryna Antonenko,Aaron Rothstein,Ronen R Leker,Issa Metanis,Edgar Samaniego,Michele Romoli,Marialuisa Zedde,Rosario Pascarella,Thanh N Nguyen,Piers Klein,Farid Khasiyev,Ossama Khazaal,Mohammad Almajali,Adeel S Zubair,Marwa Elnazeir,João Pedro Marto,Ahmad Nehme,James Anthony Giles,Stefan T Engelter,Christoph Stretz,Setareh Salehi Omran
    Source: Journal of the American Heart Association
    CONCLUSIONS: One in 6 patients with CeAD experienced a possible diagnostic error, particularly those who were younger, had migraines, or presented with headaches and nonfocal symptoms.

  • The need for whole-person care in managing community dwelling older stroke survivors

    Monday, May 04, 2026
    Author(s): Hawa O Abu,Annie Ferris,Betty Ferrell,Ann Berger
    Source: Research connections
    Stroke remains a leading cause of disability and mortality worldwide, disproportionately affecting older adults. Advances in acute stroke management have reduced mortality but led to a growing population of survivors living with long-term disability. The burden and impact of stroke extend beyond neurological impairment. Physically, older survivors experience functional decline, loss of independence in activities of daily living, and heightened need for environmental or institutional support....

  • Pathological suppression of binocular vision in stroke

    Thursday, April 30, 2026
    Author(s): Kevin E Houston,Mariam Labib,Daniel H Baker,Didem Ayturk,Asha McHenry,Samira Mortazavi,A M Barrett
    Source: Optometry and vision science : official publication of the American Academy of Optometry
    CONCLUSIONS: Denial of diplopia is associated with spatial neglect and age. In some cases, this likely represents a pathological suppression of binocular vision.

  • Filtered-phase imaging versus susceptibility-weighted imaging for paramagnetic rim lesion detection in multiple sclerosis: A head-to-head comparison

    Sunday, April 26, 2026
    Author(s): Chris Hollen,Carolina Garcia,Christopher C Hemond,Rebecca I Spain,Cole Crowson,Helen Wu,Elizabeth Silbermann
    Source: Multiple sclerosis (Houndmills, Basingstoke, England)
    CONCLUSIONS: Both techniques reliably detect PRLs with substantial inter-rater agreement. Filtered-phase imaging offers superior positive predictive value, while SWI provides better sensitivity and inter-rater reliability. Further development of a standardized training program for assessment of PRL and studies directly comparing susceptibility-sensitive sequences on different vendor platforms are warranted.

  • Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers

    Friday, April 24, 2026
    Author(s): Pierre-Louis Benveniste,Laurent Létourneau-Guillon,David Araujo,Lydia Chougar,Dumitru Fetco,Masaaki Hori,Kouhei Kamiya,Steven Messina,Charidimos Tsagkas,Bertrand Audoin,Rohit Bakshi,Elise Bannier,Daniel Blezek,Jean-Christophe Brisset,Virginie Callot,Erik Charlson,Michelle Chen,Olga Ciccarelli,Sarah Demortière,Gilles Edan,Massimo Filippi,Tobias Granberg,Cristina Granziera,Christopher C Hemond,B Mark Keegan,Anne Kerbrat,Jan Kirschke,Shannon Kolind,Pierre Labauge,Lisa Eunyoung Lee,Yaou Liu,Caterina Mainero,Julian McGinnis,Nilser Laines Medina,Mark Mühlau,Govind Nair,Kristin P O'Grady,Jiwon Oh,Russell Ouellette,Alexandre Prat,Daniel S Reich,Maria A Rocca,Timothy M Shepherd,Seth A Smith,Leszek Stawiarz,Jason Talbott,Roger Tam,Shahamat Tauhid,Anthony Traboulsee,Constantina Andrada Treaba,Paola Valsasina,Zachary Vavasour,Marios Yiannakas,Hervé Lombaert,Julien Cohen-Adad
    Source: Multiple sclerosis (Houndmills, Basingstoke, England)
    CONCLUSIONS: The proposed model can achieve accurate and reliable spinal cord MS lesion segmentation across heterogeneous MRI data, addressing a key barrier to clinical translation. The model is available in the Spinal Cord Toolbox v7.2 and higher.Code repository: https://github.com/ivadomed/seg-sc-ms-lesion-multicontrast.

  • Intra-Arterial Thrombolytic vs. Mechanical Thrombectomy in Distal Medium Middle Cerebral Artery Acute Ischemic Stroke: A Preliminary Multinational Multicenter Propensity Score-Matched Study

    Monday, April 20, 2026
    Author(s): Hamza Adel Salim,Benjamin Pulli,Vivek Yedavalli,Takahiro Ota,Dhairya Lakhani,Orabi Hajjeh,Basel Musmar,Nimer Adeeb,Fathi Milhem,Tobias D Faizy,Kareem El Naamani,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Jane Khalife,Sherief Ghozy,Luca Scarcia,Leonard L L Yeo,Benjamin Y Q Tan,Robert W Regenhardt,Jeremy J Heit,Nicole M Cancelliere,Aymeric Rouchaud,Jens Fiehler,Sunil Sheth,Ajit S Puri,Christian Dyzmann,Marco Colasurdo,Leonardo Renieri,João Pedro Filipe,Pablo Harker,Răzvan Alexandru Radu,Mohamad Abdalkader,Piers Klein,Thomas R Marotta,Julian Spears,Ashkan Mowla,Pascal Jabbour,Arundhati Biswas,Frédéric Clarençon,James E Siegler,Thanh N Nguyen,Ricardo Varela,Amanda Baker,Muhammed Amir Essibayi,David Altschul,Nestor R Gonzalez,Markus A Möhlenbruch,Vincent Costalat,Benjamin Gory,Christian Paul Stracke,Constantin Hecker,Gaultier Marnat,Hamza Shaikh,Christoph J Griessenauer,David S Liebeskind,Alessandro Pedicelli,Andrea M Alexandre,Illario Tancredi,Erwah Kalsoum,Boris Lubicz,Aman B Patel,Vitor Mendes Pereira,Max Wintermark,Adrien Guenego,Adam A Dmytriw
    Source: Clinical neuroradiology
    CONCLUSION: For MCA DMVO, IAT showed similar functional outcomes and numerically fewer safety events than MT despite lower recanalization rates. These findings should be interpreted cautiously, given the small IAT sample size and require validation in larger prospective studies.

  • Reachable Workspace as a Clinical Outcome for Upper Extremity Function: A Narrative Review

    Friday, April 10, 2026
    Author(s): Jay J Han,Lawrence J Hayward,Christina Adams,Juan Perez-Ibarra
    Source: Muscle & nerve
    Motion sensing technology can be utilized to capture detailed upper extremity (UE) motion to reconstruct an individual's three-dimensional (3D) reachable workspace (RWS). The RWS can be quantified as relative surface area (RSA), providing an innovative surrogate measure to assess UE mobility and function. Numerous studies have shown that RSA can reliably distinguish between healthy and impaired UE function and also is able to detect clinically relevant longitudinal changes, with sufficient...

  • Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis

    Tuesday, March 31, 2026
    Author(s): Paul J Hop,Maarten Kooyman,Brendan J Kenna,Ramona A J Zwamborn,Kristel R van Eijk,Yan Wang,Charlotte H van Dijk,Erwin Bekema,Wouter van Rheenen,Paul Beele,Joke J F A van Vugt,Project MinE ALS sequencing Consortium,NYGC ALS Consortium,FALS sequencing Consortium,GTAC Consortium,Ahmad Al Khleifat,Alfredo Iacoangeli,Johnathan Cooper-Knock,Bradley N Smith,Simon Topp,Anneke J van der Kooi,Vera Fominykh,Vivian Drory,Yossef Lerner,Yehuda Shovman,Dominic B Rowe,Kelly L Williams,Russell L McLaughlin,Jessica Hurt,Yunfeng Huang,Chia-Yen Chen,Ellen Tsai,Heiko Runz,Eleonora Aronica,Ewout J N Groen,Michael A van Es,R Jeroen Pasterkamp,Sali M K Farhan,Fleur C Garton,Allan F McRae,Pamela A McCombe,Robert D Henderson,Dongsheng Fan,Lenka Šlachtová,Helle Høyer,Agnes L Nishimura,Ruben J Cauchi,Lev Brylev,Boris Rogelj,Blaž Koritnik,Janez Zidar,Teresa Salas,Jesus S Mora Pardina,Marc Gotkine,Monica Povedano,Philippe Corcia,Patrick Vourc'h,Philippe Couratier,Markus Weber,Matthew C Kiernan,Roger Pamphlett,Ian P Blair,Mamede de Carvalho,Nazli A Başak,Caroline Ingre,Peter M Andersen,Lorne Zinman,Ekaterina Rogaeva,Ian R MacKenzie,Nicolas Dupre,Guy A Rouleau,Bryan J Traynor,Nicola Ticozzi,Adriano Chiò,Vincenzo Silani,Orla Hardiman,Hemali Phatnani,Matthew B Harms,Clifton L Dalgard,Jonathan D Glass,John E Landers,Philip Van Damme,Karen E Morrison,Pamela J Shaw,Chris E Shaw,Ammar Al-Chalabi,Leonard H van den Berg,Kevin P Kenna,Jan H Veldink
    Source: Nature genetics
    Amyotrophic lateral sclerosis (ALS) is a heritable disorder where rare variants with low-to-moderate penetrance are thought to dominate genetic risk. To identify such rare variants, we harmonized and analyzed exome data from 22 cohorts, totaling 17,919 individuals with ALS and 200,703 controls across discovery and replication phases. Rare variant analyses identified several new risk genes, with replication confirming association of YKT6 and supporting HTR3C, GBGT1 and KNTC1. We also provide...

  • The burden of bone disease in Duchenne muscular dystrophy: age-specific prevalence of osteoporosis and low bone density

    Monday, March 30, 2026
    Author(s): Nat Nasomyont,Cuixia Tian,Lindsey Hornung,Jane Khoury,Brenda L Wong,Meilan M Rutter
    Source: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
    CONCLUSIONS: Osteoporosis, fractures, and low BMD were highly prevalent from a young age in children and adolescents with DMD and increased progressively with age and GC exposure. The prevalence of osteoporosis reflected the cumulative acquisition of vertebral fractures, consistent with long-term GC effect. These data highlight the urgent need to improve early detection and prevention of osteoporosis in individuals with DMD.

  • Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

    Monday, March 30, 2026
    Author(s): GBD 2023 Meningitis & Antimicrobial Resistance Collaborators
    Source: The Lancet. Neurology
    BACKGROUND: Meningitis remains the leading infectious cause of neurological disabilities globally, disproportionately affecting children younger than 5 years and populations in the African meningitis belt. Whereas previous global estimates focused on ten pathogen categories, this study presents the most comprehensive analysis to date, assessing the meningitis burden attributable to 17 causative pathogens based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023...

  • Adeno-Associated Virus Toxicity in Duchenne Muscular Dystrophy: Mechanisms and Clinical Considerations

    Saturday, March 28, 2026
    Author(s): Ezgi Saylam,Eleonora S D'ambrosio,Maria Tozzo Pesco,Liubov V Gushchina
    Source: Genes
    Background/Objectives: Recombinant adeno-associated virus (AAV) vectors have revolutionized gene therapy for monogenic diseases such as Duchenne muscular dystrophy (DMD). However, high systemic doses required for muscle transduction cause a spectrum of toxicities ranging from transient hepatic inflammation to fatal multi-organ failure leading to death. These adverse events have reshaped the risk-benefit considerations for gene therapy in DMD. Methods: We conducted a narrative review describing...

  • Duchenne Muscular Dystrophy: Contemporary Therapeutic Options and Real-World Challenges in Treatment Selection

    Friday, March 27, 2026
    Author(s): Maria Tozzo Pesco,Gülru Zeynep Öztürk,Shivkumar C Bhadola,Stephen M Chrzanowski,Liubov V Gushchina,Eleonora S D'Ambrosio
    Source: Muscles (Basel, Switzerland)
    Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular disorder caused by loss-of-function mutations in the dystrophin gene, leading to progressive muscle degeneration, motor decline, respiratory compromise, and cardiomyopathy. Diagnosis typically occurs in early childhood following recognition of motor delays, markedly elevated creatine kinase, and confirmatory genetic testing. Over the past decade, the therapeutic landscape for DMD has expanded substantially, evolving from...

  • Nonoperative management of patients with symptomatic carotid stenosis

    Monday, March 23, 2026
    Author(s): Matthew Yen,Larry B Goldstein,Brian Silver,Seemant Chaturvedi
    Source: Seminars in vascular surgery
    The interventional management of symptomatic carotid disease (ie, endarterectomy, angioplasty/stenting, or transcarotid artery revascularization) has traditionally involved correcting the area of arterial narrowing, guided by stenosis severity combined with medical therapy, and has been recommended by the 2021 American Heart Association Secondary Stroke Prevention Guidelines. Despite this traditional practice, advances in medical therapy show promise in reducing recurrent stroke without the need...

  • CT Angiogram-Based Risk Stratification of Nonstenotic Carotid Plaques: An Important Step Forward

    Tuesday, March 17, 2026
    Author(s): Thomas R Ford,Brian Silver
    Source: Neurology
    No abstract

  • Alexander Disease: A Literature Review for Clinicians

    Monday, March 16, 2026
    Author(s): Maria Tozzo Pesco,Jun Xie,Eleonora Silvana D'Ambrosio
    Source: Journal of child neurology
    Alexander disease (ALEXD; MIM 203450) is a rare leukodystrophy caused by dominant mutations in the GFAP (Glial Fibrillary Acidic Protein) gene, which encodes a key structural protein of astrocytes. First described in 1949, ALEXD is now recognized as a clinically heterogeneous disorder with a broad phenotypic spectrum spanning neonatal, infantile, juvenile, and adult-onset forms. Clinical manifestations vary according to age at onset and disease subtype, ranging from early developmental...

  • Selective chr21 homolog silencing reveals polymorphisms influence the epigenetic silencing and functional dosage of RWDD2B

    Saturday, March 14, 2026
    Author(s): Eric C Larsen,Jennifer E Moon,Oliver D King,Jeanne B Lawrence
    Source: American journal of human genetics
    Polymorphisms that affect chromosome 21 (chr21) gene expression have significance for both variable severity in Down syndrome and common multifactorial conditions. Here, results demonstrate that "selective homolog silencing" in cells from one individual can provide a valuable complement to population-level studies. In trisomic induced pluripotent stem cell (iPSC) subclones that silence different chr21 homologs (via XIST-based silencing), we discovered unusually large, homolog-specific...

  • A high-throughput, quantitative platform using 2D dissociated human cerebral organoids to model neuroinflammation in Alzheimer's disease

    Thursday, March 12, 2026
    Author(s): Meagan N Olson,Nathaniel J Barton,Luyao Feng,Samantha M Chigas,Khanh Tran,Adrian R Orszulak,Jafira M Johnson,Pepper Dawes,Chandani Shrestha,Vishali R Umaiyalan,Yen-Hsiang Huang,Jonathan Sundstrom,Liam F Murray,Qi Wang,Hyung Suk Oh,Megan H Orzalli,David M Knipe,Benjamin Readhead,Yingleong Chan,Elaine T Lim
    Source: NPJ dementia
    Neuroinflammation is a key process associated with Alzheimer's disease (AD). There is interest in developing New Approach Methodologies (NAMs) by using human in-vitro complex systems such as brain organoids, combined with machine learning and computational approaches, to reproducibly and robustly evaluate monoclonal antibodies and other therapeutic modalities on these human-derived systems. Herpesviruses such as herpes simplex virus 1 (HSV-1) had been shown to be associated with AD risk and...

  • SORT LNPs encapsulating Cas9 mRNA achieve efficient editing in skeletal muscle in a dystrophic mouse model

    Thursday, March 12, 2026
    Author(s): Sukanya Iyer,Katelyn Daman,Yehui Sun,Amanda Tutto,Sarah E Holbrook,Anya T Joynt,Jing Yan,Prajakta Ambegaokar,Dongsheng Guo,Pengpeng Liu,Jennifer E Stauffer,Stacy A Maitland,Sang M Lee,Yufen Xiao,Hsi-Chien Huang,Lihua J Zhu,Thomas L Gallagher,Gregory A Cox,Allison M Keeler,Daniel J Siegwart,Charles P Emerson,Scot A Wolfe
    Source: Molecular therapy : the journal of the American Society of Gene Therapy
    Limb girdle muscular dystrophy (LGMD) is the fourth most common type of muscular dystrophy. Gene editing holds promise for treating neuromuscular disorders such as LGMD, but clinical translation remains challenging due to lack of complementary delivery tools for skeletal muscle. Lipid nanoparticles (LNPs) offer a promising platform for transient delivery of gene-editing reagents as mRNA or ribonucleoprotein complexes (RNPs) to skeletal muscle, but editing efficiencies remain modest. While lipid...

  • Sex-Related Differences in Outcomes of Endovascular Treatment of Distal Medium Vessel Occlusion Strokes

    Tuesday, March 10, 2026
    Author(s): Hamza Adel Salim,Vivek Yedavalli,Dhairya Lakhani,Fathi Milhem,Basel Musmar,Nimer Adeeb,Davide Simonato,Yan-Lin Li,Orabi Hajjeh,Muhammed Amir Essibayi,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Jane Khalife,Sherief Ghozy,Luca Scarcia,Leonard Ll Yeo,Benjamin Yq Tan,Robert W Regenhardt,Jeremy J Heit,Aymeric Rouchaud,Jens Fiehler,Sunil Sheth,Ajit S Puri,Christian Dyzmann,Marco Colasurdo,Leonardo Renieri,João Pedro Filipe,Pablo Harker,Răzvan Alexandru Radu,Mohamad Abdalkader,Piers Klein,Takahiro Ota,Ashkan Mowla,Kareem El Naamani,Pascal Jabbour,Arundhati Biswas,Frédéric Clarençon,James E Siegler,Thanh N Nguyen,Ricardo Varela,Amanda Baker,David Altschul,Nestor R Gonzalez,Markus A Möhlenbruch,Vincent Costalat,Benjamin Gory,Christian Paul Stracke,Constantin Hecker,Gaultier Marnat,Hamza Shaikh,Christoph J Griessenauer,David S Liebeskind,Alessandro Pedicelli,Andrea M Alexandre,Tobias D Faizy,Illario Tancredi,Erwah Kalsoum,Boris Lubicz,Aman B Patel,Maurizio Fuschi,Max Wintermark,Adrien Guenego,Adam A Dmytriw
    Source: Clinical neuroradiology
    CONCLUSIONS: After adjustment for age, baseline disability, and vascular risk factors, biological sex was not independently associated with functional or safety outcomes following mechanical thrombectomy for DMVO stroke.

  • Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression

    Monday, March 09, 2026
    Author(s): Gianluca Corazzolla,Constantina A Treaba,Mehrbod Mohammadian,Ludovica Brusaferri,Valeria Barletta,Nicole R Zürcher,Jacob M Hooker,Jacob Sloane,Eric Klawiter,Roberto Bomprezzi,Maria A Rocca,Massimo Filippi,Marco L Loggia,Caterina Mainero
    Source: Brain : a journal of neurology
    The skull bone marrow contributes to brain immune homeostasis via recently discovered skull-meningeal channels, enabling the bidirectional trafficking of immune cells between skull bone and underlying dura mater. In multiple sclerosis, autoreactive T cells migrate to the bone marrow and shift its hematopoietic output toward myeloid differentiation, contributing to disease progression. However, the role of the skull bone marrow in multiple sclerosis pathophysiology, and its relationship to brain...

  • Breaking β-sheets in FUS prion-like domain preserves phase separation and function but prevents aggregation and toxicity

    Friday, February 27, 2026
    Author(s): Noah Wake,Juan Alcalde,Daniel Jutzi,Anjali Bajaj,Sukhleen Kour,Mayur Barai,Shuo-Lin Weng,Samara Cummings,Tongyin Zheng,Eric N Anderson,Szu-Huan Wang,Ryan Puterbaugh,Daryl A Bosco,Benjamin S Schuster,Jeetain Mittal,Udai Bhan Pandey,Marc-David Ruepp,Nicolas L Fawzi
    Source: bioRxiv : the preprint server for biology
    The RNA-binding protein Fused in Sarcoma (FUS) undergoes phase separation associated with RNA processing. However, the prion-like low complexity (LC) domain of FUS forms solid-like aggregates in neurodegenerative diseases. Whether the formation of β-sheet structure associated with pathology is also physiologically/functionally relevant is debated. Similarly, if mislocalization alone or concomitant aggregation is responsible for FUS gain-of-function toxicity remains to be probed. Here, we...

  • Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case

    Monday, February 16, 2026
    Author(s): Brittany Owusu- Adjei,Janelle P Renterghem,Cristina Hayes Meizoso,Rrita Daci,Constance J Mietus,Peter S Amenta,Mark D Johnson,David Cachia
    Source: Journal of neurosurgery. Case lessons
    BACKGROUND: Isocitrate dehydrogenase (IDH) is a commonly mutated gene in gliomas. Although IDH-mutant WHO grade 4 astrocytomas tend to occur in younger patients and show an improved survival compared to IDH-wildtype, prognosis remains poor and treatment options are limited. Ivosidenib is a small-molecule inhibitor of IDH-1 that has shown promise for treating low-grade IDH-mutant glioma. However, little is known about its efficacy in IDH-mutant WHO grade 4 astrocytoma.

  • A Roadmap to Neurologic Health Equity: An AAN Position Statement

    Wednesday, February 11, 2026
    Author(s): Payal B Patel,Roy H Hamilton,Joshua Amit Budhu,Samir R Belagaje,Gregory Eugene Cooper,Franklyn Rocha Cabrero,Anindita Deb,Veronica E Santini,Rashmi Halker,Tiffany L Fisher,Charles C Flippen,Eseosa Ighodaro,Nicole Rosendale,Vijay K Ramanan,Kiran Teresa Thakur,Nimish A Mohile
    Source: Neurology
    Neurologic disorders affect more than 200 million people in the United States, yet inequities in neurologic health persist particularly among marginalized populations. These disparities are rooted not in biological differences but in inequitable social, economic, and structural conditions and result in disproportionate disease burden, delayed diagnoses, restricted access to specialty care, and subpar brain health outcomes for populations experiencing health disparities (HDPs). Existing national...

  • A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study

    Friday, February 06, 2026
    Author(s): Nicol C Voermans,Jeffrey M Statland,Lawrence J Hayward,Angela Rosenbohm,Adolfo López de Munain,Sabrina Sacconi,Doris G Leung,Umesh A Badrising,John Vissing,Benedikt Schoser,Nuria Muelas,Hanns Lochmüller,Enrico Bugiardini,Leo H Wang,Lorenzo Maggi,Thomas Ragole,Alan Pestronk,Johanna I Hamel,Namita A Goyal,Lawrence Korngut,Elie Naddaf,Amy Harper,Perry B Shieh,Cornelia Kornblum,Valeria Sansone,Angela Genge,Giorgio Tasca,John Jiang,Marie-Helene Jouvin,Rabi Tawil,REACH Investigators
    Source: Journal of neuromuscular diseases
    CONCLUSIONS: Losmapimod was generally well tolerated with a favorable safety profile at a dose of 15 mg twice daily. Although none of the efficacy endpoints were met, study design and data from the study may inform future studies of FSHD therapies.

  • Blocking RAN translation without altering repeat RNAs rescues C9ORF72-related ALS and FTD phenotypes

    Thursday, February 05, 2026
    Author(s): Xin Jiang,Laure Schaeffer,Divya Patni,Tommaso Russo,Chao-Zong Lee,Corey Aguilar,Christine Marques,Karen Jansen-West,Marian Hruska-Plochan,Ananya Ray-Soni,Su Min Lim,Aaron Held,Mei Yue,Paula Castellanos Otero,Sandeep Aryal,Hortense D A M Beaussant,Himanish Basu,Hiro Takakuwa,Lillian M Daughrity,Nandini Ramesh,Paulo Da Costa,Ana Rita A A Quadros,Matthew Nolan,Charles Jourdan F Reyes,Hayden Wheeler,Laura C Moran,Grant Griesman,Benjamin Wymann,Bianca A Trombetta,Emma Sofia Lopez-De-Silanes,Michael Canori,Gopinath Krishnan,Yasmim Vieira Souza Da Silva,Gilbert Eriani,Mark W Albers,Steven E Arnold,Yuyu Song,Ankur Jain,Isaac M Chiu,Yong-Jie Zhang,Fen-Biao Gao,Brian J Wainger,Magdalini Polymenidou,Leonard Petrucelli,Franck Martin,Clotilde Lagier-Tourenne
    Source: Science (New York, N.Y.)
    GGGGCC (G(4)C(2)) repeat expansion in C9ORF72 is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Toxicity is thought to result from the accumulation of either repeat RNAs and/or dipeptide repeat proteins (DPRs) translated from repeat-containing transcripts through repeat-associated non-AUG (RAN) translation. To disentangle RNA from DPR toxicity, we mutated a CUG codon predominantly used to initiate DPR translation from all three reading...

  • Reliable repurposing of the antibody interactome inside the cell

    Saturday, January 31, 2026
    Author(s): Caitlin M O'Shea,Rushba Shahzad,Kimia Aghasoleimani,Stuart Newman,Jiraporn Panmanee,Leonard C Schalkwyk,Greg N Brooke,Fiona E Benson,James S Trimmer,Daryl A Bosco,Takao Fujisawa,Hidenori Ichijo,Neil R Cashman,Stanislav Engel,Gareth S A Wright
    Source: Nature communications
    Eighty-five percent of the human proteome has at least one interacting monoclonal antibody. These molecules penetrate the cytoplasm poorly and are very often non-functional within the cell. Analysis of antibody variable domains and characterisation of forty-five single-chain variable fragment (scFv) intrabodies expressed in human cells indicated charge to have the greatest impact on solubility. We created new interdomain linkers, optimised scFv domain orientation and found an optimisable charge...

  • Dissecting Aneurysm in Cervical Artery Dissection: Insights From the STOP-CAD Study

    Thursday, January 29, 2026
    Author(s): Muhib Khan,Zafer Keser,Liqi Shu,Elizabeth Lee,Melanie Ho,Piers Klein,Dania Mallick,Kim Griffin,Daniel Mandel,Ronen R Leker,Issa Metanis,Balaji Krishnaiah,Setareh Omran,Reza Bavarsad Shahripour,Ekaterina Bakradze,Nils Henninger,Stefan T Engelter,Mirjam R Heldner,Kateryna Antonenko,James E Siegler,João Pedro Marto,Aaron Rothstein,Ossama Khazaal,Christian H Nolte,Ross Crandall,Evan Lester,Ahmad Nehme,Brian Mac Grory,Malik Ghannam,Mohammad Almajali,Marwa Elnazeir,Sami Al Kasab,Daniyal Asad,Anvesh Balabhadra,Ana Catarina Fonseca,Diana Cruz,Michele Romoli,Faddi Saleh Velez,Alexis N Simpkins,Shayak Sen,Marialuisa Zedde,Edgar A Samaniego,Adeel Zubair,Christoph Stretz,Wayneho Kam,Mohamad Abdalkader,Shadi Yaghi,Thanh N Nguyen
    Source: Stroke
    CONCLUSIONS: DAs are relatively common manifestations of CeAD, typically occurring within 6 months of CeAD diagnosis. DA was not associated with an increased risk of subsequent ischemic stroke or intracranial hemorrhage.

  • Antithrombotic Trends Before and After Publication of Randomized Clinical Trials in Cervical Artery Dissection: A Secondary Analysis of the STOP-CAD Study

    Friday, January 23, 2026
    Author(s): Mary Penckofer,Liqi Shu,Lukas Strelecky,Shadi Yaghi,Nils Henninger,Jayachandra Muppa,Ekaterina Bakradze,Mirjam R Heldner,Kateryna Antonenko,Setareh Salehi Omran,David J Seiffge,Marcel Arnold,Marialuisa Zedde,Adeel Zubair,João Pedro Marto,Malik Ghannam,Stefan Engelter,Christopher Traenka,Brian Mac Grory,Wayneho Kam,Marwa Elnazeir,Michele Romoli,Faddi G Saleh Velez,James E Siegler
    Source: Stroke (Hoboken, N.J.)
    CONCLUSION: These real-world clinical practice data indicate a decline in the use and duration of oral anticoagulation for acute cervical artery dissection.

  • Mislocalization of FTD3-associated mutant CHMP2B to the nucleus of human neurons due to loss of a nuclear export signal

    Tuesday, January 20, 2026
    Author(s): Yong-Woo Jun,Evan P Hass,Soojin Lee,Thomas G Fazzio,Fen-Biao Gao
    Source: Acta neuropathologica communications
    Frontotemporal dementia linked to chromosome 3 (FTD3) is caused by a splice site point mutation in CHMP2B, resulting in the production of mutant proteins CHMP2B^(In5) and CHMP2B^(Δ10). Here, we found that wildtype CHMP2B (CHMP2B^(WT)) is mostly present in the cytoplasm, but CHMP2B^(In5) is mislocalized to the nucleus of human induced pluripotent stem cell (iPSC)-derived cortical neurons. To understand the underlying mechanism, we identified a previously unreported nuclear export signal (NES) in...

  • Cervical Artery Dissection Diagnosed Following Chiropractic Cervical Manipulation: A STOP-CAD Subanalysis

    Tuesday, January 20, 2026
    Author(s): Rozaleen Aleyadeh,Marialuisa Zedde,Joao P Marto,Nils Henninger,Jamil Said,Jennifer A Frontera,Richa Sharma,Ronen R Leker,Thais L Secchi,Fransisca Indraswari,Abid Y Quereshi,Lily W Zhou,Alexandre Y Poppe,Hipolito Nzwalo,Victor C Wall,Ana C Fonseca,Piers Klein,David S Liebeskind,Sheila C O Martins,Malik Ghannam,Vishnu Dantu,Jorge G Ortiz Gracia,Giovanna De Marco,Ekaterina Bakradze,Mary Penckofer,Anvesh Balabhadra,Setareh S Omran,Christopher Chang,Christopher R Leon Guerrero,Varsha Muddasani,Regina von Rennenberg,Xiaofan Guo,Cheran Elangovan,Mohammad AlMajali,Faddi S Velez,Reza B Shahripour,Daniel M Mandel,Adeel Zubair,Marwa Elnazeir,Balaji Krishnaiah,Christoph Stretz,Shadi Yaghi,Nancy Maalouf
    Source: The neurologist
    CONCLUSIONS: Given the very high number of manipulations performed annually, the absolute risk of secondary CeAD is extremely low. Manipulation-associated cases have distinct clinical features, occurring more often in younger women with vertebral dissections. Whether manipulation acts as a precipitating trigger or patients with early CeAD symptoms seek manipulation remains unresolved.

  • Early prediction of Alzheimer's disease using longitudinal electronic health records of US military veterans

    Monday, January 12, 2026
    Author(s): Rumeng Li,Dan Berlowitz,Jesse Mez,Brian Silver,Xun Wang,Wen Hu,Raelene Goodwin,Heather Keating,Weisong Liu,Honghuang Lin,Hong Yu
    Source: Communications medicine
    CONCLUSIONS: Signs and symptoms of early Alzheimer's disease are reported in clinical notes many years before a clinical diagnosis is made and the frequency of these signs and symptoms, approximated by keywords, increases the closer one is to the diagnosis. A simple keyword-based approach can capture these signals and can help identify individuals at high risk of future Alzheimer's disease.

  • Recurrent Cervical Artery Dissection Prevalence and Predictors: A Secondary Analysis of the STOP-CAD Study

    Monday, January 12, 2026
    Author(s): João Pedro Marto,Liqi Shu,Eileen Wu,Daniel M Mendel,Mirjam R Heldner,Josefin E Kaufmann,Ronen R Leker,Marialuisa Zedde,Ahmad Nehme,Jayachandra Muppa,Diana Aguiar de Sousa,João André Sousa,Ana Catarina Fonseca,Hipólito Nzwalo,Michele Romoli,Setareh Salehi Omran,Zafer Keser,Reza Bavarsad Shahripour,Wayneho Kam,Adeel S Zubair,Faddi Ghassan Saleh Velez,Cheran Elangovan,Balaji Krishnaiah,Issa Metanis,Rosario Pascarella,James E Siegler,Aaron Rothstein,Ossama Khazaal,Kateryna Antonenko,Alexis N Simpkins,Evan Lester,Ross Crandall,Sara Rosa,Mafalda Soares,Ekaterina Bakradze,Joshua Z Willey,Malik Ghannam,Edgar A Samaniego,Marwa Elnazeir,Piers Klein,Christopher Traenka,Nils Henninger,Thanh N Nguyen,Stefan T Engelter,Shadi Yaghi
    Source: Stroke
    CONCLUSIONS: In this retrospective study, recurrent CeAD was uncommon, approximately half of the events were diagnosed within the first 2 months of the index event, and recurrent events rarely caused new ischemic events. Younger age, migraine, absence of ischemic stroke at presentation, and signs of fibromuscular dysplasia may help identify high-risk patients.

  • Effects of Intradural Extension of Extracranial Cervical Artery Dissection on Outcomes: A Secondary Analysis From the STOP-CAD Study

    Thursday, January 08, 2026
    Author(s): Issa Metanis,Liqi Shu,Favour Akpokiere,Hamza Jubran,Daniel M Mandel,Christian H Nolte,James E Siegler,Stefan T Engelter,Brian Mac Grory,Jennifer Frontera,Muhib Khan,Aaron Rothstein,Yoel Schwartzmann,João Pedro Marto,Marialuisa Zedde,Alexandre Y Poppe,Tamer Jubeh,Zafer Keser,Mohammad AlMajali,Fatma Shalabi,Nils Henninger,Kateryna Antonenko,Mirjam R Heldner,Sara Rosa,Ossama Khazaal,Josefine E Kaufman,Christopher Traenka,Ekaterina Bakradze,Adeel Zubair,Tamra Ranasinghe,João André Sousa,Gabriel Paulo Mantovani,Alexis N Simpkins,Setareh Salehi Omran,Joao Sargento-Freitas,Marwa Elnazeir,Diana Aguiar de Sousa,Shadi Yaghi,Ronen R Leker
    Source: Annals of neurology
    OBJECTIVE: Cervical artery dissection (CeAD) may be limited to the extracranial extradural space or extend to the intradural space. Intradural extension can potentially increase the risk of stroke and subarachnoid hemorrhage. However, the factors associated with intradural extension and its impact on clinical outcome remain unclear.

  • Interpreting Neonatal hyperCKemia Identified Through Duchenne Muscular Dystrophy Newborn Screening: A Predictive Model Based on Maternal, Labor, Delivery and Newborn Factors

    Wednesday, January 07, 2026
    Author(s): Elisa N Falk,Stephen M Chrzanowski,Francesca Coyne,Yvonne Sheldon,Sara Cherkerzian,Richard B Parad
    Source: Muscle & nerve
    INTRODUCTION/AIMS: With implementation of newborn screening (NBS) for Duchenne muscular dystrophy (DMD), creatine kinase-muscle (CK) values will be reported on newborns. Maternal, labor, delivery, and newborn factors may elevate CK levels, raising concern for DMD. Predictive modeling could aid hyperCKemia interpretation while awaiting diagnostic confirmation.

  • Intravenous Thrombolysis in Patients on Direct Oral Anticoagulants: Analysis of the Get With The Guidelines Stroke Registry

    Tuesday, December 30, 2025
    Author(s): Shadi Yaghi,Liqi Shu,Eva A Mistry,Opeolu Adeoye,Lee Schwamm,Steven Messe,Mitchell S V Elkind,Malik Ghannam,Adam de Havenon,Karen Furie,Ying Xian,Christopher Streib,Runqi Wangqin,Nils Henninger,Jeffrey L Saver,Eric E Smith
    Source: Journal of the American Heart Association
    CONCLUSIONS: In this study, intravenous thrombolysis was associated with improved functional outcomes in patients with recent DOAC use and appeared safe. Given the study limitations, findings require validation by prospective trials.

  • Imaging in Movement Disorders: A Clinician's Perspective on Novel Applications

    Friday, December 26, 2025
    Author(s): Kara M Smith,Manojkumar Saranathan
    Source: Seminars in neurology
    The utility of neuroimaging in the diagnosis and management of movement disorders has been steadily increasing as both imaging and image analysis technologies have advanced in the last decade. Neuroimaging is also playing a critical role in the search for novel therapies to prevent, slow down, and treat various movement disorders. This article reviews both standard and innovative imaging tools available for both clinicians and researchers. We focus predominantly on the clinician's perspective,...

  • Heart Transplantation and Ventricular Assist Device in Duchenne Muscular Dystrophy: A New Era

    Monday, December 22, 2025
    Author(s): David N Rosenthal,Antonio Amodeo,Russell J Butterfield,Ryan Butts,Stephen Chrzanowski,Linda Cripe,John Day,Ryan Davies,Tina Duong,Patrick Evers,Katheryn Gambetta,Rachel Harris,Emily Hayes,Beth Kaufman,Angela Lorts,Gordon Mack,Samuel J Mackenzie,Pradeep Mammen,Larry Markham,Jennifer McAlister,Craig McDonald,Stephanie J Nakano,Deipanjan Nandi,Manchula Navaratnam,Stanley Nelson,John J Parent,Cara Piccoli,Marc Richmond,Carolina Rocha,Hemant Sawnani,Rachel Schrader,Richard Shell,Renata Shih,Svetlana Shugh,Theodore Smart,John Soslow,Joseph Spinner,Tanja Taivassalo,Hari Tunugtla,Christina VanderPluym,Aravindhan Veerapandiyan,Chet Villa,Carol Wittlieb-Weber,Marwa Zafarullah,Seth Hollander
    Source: Pediatric transplantation
    Duchenne muscular dystrophy (DMD) is an X-linked genetic neuromuscular disorder that is caused by a mutation in the dystrophin gene. The disease is characterized by progressive weakness of skeletal muscle, resulting in loss of ambulation and eventually respiratory insufficiency. Cardiac muscle is also involved, and cardiomyopathy is a prominent feature of DMD. The care of patients with DMD has changed in important ways over the past 15 years, with the use of chronic steroid therapy combined with...

  • The Ku80-p53-SIRT1 axis in DNA damage response contributes to sporadic and familial ALS and FTD

    Saturday, December 20, 2025
    Author(s): Yong-Woo Jun,Soojin Lee,Sandra Almeida,Kristine K Freude,Justin K Ichida,Fen-Biao Gao
    Source: Nature communications
    Although TDP-43 pathology is found in most sporadic and familial ALS and FTD cases, other shared pathogenic mechanisms remain largely unknown. Here we show that SIRT1 levels are decreased and acetylated p53 levels are increased in iPSC-derived neurons from sALS patients and with the FTD3-causing CHMP2B mutation. Ectopic expression of SIRT1 in these patient neurons rescues neurodegeneration and reduces acetylated p53 levels. DNA damage is elevated in both sALS and FTD3 neurons, leading to...

  • Need for Engagement in Stroke Prevention Shared Decision-Making in Older Adults with Atrial Fibrillation and Multimorbidity

    Friday, December 19, 2025
    Author(s): Hawa O Abu,Jane S Saczynski,Michelle Nabi,Annie Ferris,Mayra Tisminetzky,Jerry H Gurwitz,Kathleen Mazor,Robert J Goldberg,David Dosa,Alok Kapoor,Daniel Matlock,David D McManus
    Source: Advances in geriatric medicine and research
    CONCLUSIONS: Clinicians should recognize the specific needs of older patients with AF and multimorbidity that seek greater involvement in SDM for stroke prevention. Providing tailored interventions can enhance stroke prevention decision-making in this vulnerable population.

  • Acceptable standards for clinic-based digital cognitive assessments: Recommendations from the Global CEO Initiative on Alzheimer's Disease

    Wednesday, December 17, 2025
    Author(s): Louisa I Thompson,Barak Gaster,Dustin B Hammers,Sol Fittipaldi,A M Barrett,Katherine A Partrick,Emily Scholler,Benjamin Tiede,Christopher R Butler,CEOi Digital Cognitive Assessment Workgroup
    Source: Alzheimer's & dementia : the journal of the Alzheimer's Association
    The rising prevalence of mild cognitive impairment (MCI) and dementia, combined with persistent underdiagnosis, is driving an increased need for scalable cognitive assessment tools. Digital cognitive assessments (DCAs) offer a promising solution by addressing longstanding barriers to routine cognitive testing and diagnosis. However, variations in performance and intended use have created confusion about their clinical applications and utility. The Global CEO Initiative on Alzheimer's Disease...

  • Epigenetic clocks and longitudinal plasma biomarkers of Alzheimer's disease

    Tuesday, December 16, 2025
    Author(s): Bowei Zhang,Linda K McEvoy,Steve Nguyen,Mark A Espeland,Stephen R Rapp,Steve Horvath,Ake T Lu,Andrea Z LaCroix,Caroline M Nievergelt,Adam X Maihofer,Susan M Resnick,Michelle M Mielke,Kenneth Beckman,Danni Li,Brian Silver,JoAnn E Manson,Luigi Ferrucci,Aladdin H Shadyab
    Source: Alzheimer's & dementia : the journal of the Alzheimer's Association
    INTRODUCTION: Chronological age is the strongest risk factor for Alzheimer's disease and related dementias (ADRD). However, the association of accelerated biological aging relative to chronological age with ADRD pathology is unclear.

  • Response to "Enhancing the XGBoost Mortality Prediction Model for ICU Patients with Acute Ischemic Stroke"

    Thursday, December 11, 2025
    Author(s): Jack A Cummins,Ben S Gerber,Mayuko Ito Fukunaga,Nils Henninger,Catarina I Kiefe,Feifan Liu
    Source: Health data science
    No abstract

  • Intravenous Thrombolysis in Distal Medium Middle Cerebral Artery Occlusion Patients with Unsuccessful Mechanical Reperfusion

    Tuesday, November 25, 2025
    Author(s): Hamza Adel Salim,Benjamin Pulli,Vivek Yedavalli,Dhairya Lakhani,Orabi Hajjeh,Basel Musmar,Nimer Adeeb,Fathi Milhem,Davide Simonato,Yan-Lin Li,Muhammed Amir Essibayi,Nils Henninger,Sri Hari Sundararajan,Anna Luisa Kühn,Jane Khalife,Sherief Ghozy,Luca Scarcia,Leonard L Yeo,Benjamin Y Q Tan,Robert W Regenhardt,Aymeric Rouchaud,Jens Fiehler,Sunil Sheth,Ajit S Puri,Christian Dyzmann,Marco Colasurdo,Leonardo Renieri,João Pedro Filipe,Pablo Harker,Răzvan Alexandru Radu,Mohamad Abdalkader,Piers Klein,Takahiro Ota,Ashkan Mowla,Kareem El Naamani,Pascal Jabbour,Arundhati Biswas,Frédéric Clarençon,James E Siegler,Thanh N Nguyen,Ricardo Varela,Amanda Baker,David Altschul,Nestor R Gonzalez,Markus A Möhlenbruch,Vincent Costalat,Benjamin Gory,Christian Paul Stracke,Constantin Hecker,Gaultier Marnat,Hamza Shaikh,Christoph J Griessenauer,David S Liebeskind,Alessandro Pedicelli,Andrea M Alexandre,Tobias D Faizy,Illario Tancredi,Erwah Kalsoum,Boris Lubicz,Vitor Mendes Pereira,Aman B Patel,Maurizio Fuschi,Max Wintermark,Jeremy J Heit,Adrien Guenego,Adam A Dmytriw,MAD MT Investigators
    Source: Clinical neuroradiology
    CONCLUSIONS: In AIS patients with DMVO and unsuccessful or partial recanalization after MT, IVT did not significantly improve clinical outcomes. Additionally, IVT did not increase the risk of hemorrhagic complications. These findings suggest that while IVT preceding MT is safe in this context, it may not improve outcomes for patients with unsuccessful MT.

  • Preliminary Psychometric Review of Neurologists' Speech Ratings on the Unified Parkinson's Disease Rating Scale

    Tuesday, November 18, 2025
    Author(s): Kimberly L Dahl,Magdalen A Balz,Kara M Smith,Cara E Stepp
    Source: American journal of speech-language pathology
    CONCLUSIONS: A critical communication outcome-intelligibility during unscripted speech-is not captured by MDS-UPDRS Part III speech ratings, suggesting weak concurrent validity of this widely used metric of speech function. The reproducibility of MDS-UPDRS Part III speech ratings across providers is fair. These speech ratings may be insufficient to assess the speech function of people with PD and identify those in need of speech services.

  • Contralaterally Controlled Functional Electrical Stimulation for Upper Extremity Recovery Following Stroke: A Multisite Randomized Controlled Trial

    Thursday, November 13, 2025
    Author(s): Jayme S Knutson,Amy S Friedl,Kristine M Hansen,Mary Y Harley,Shannon D Hogan,David A Cunningham,Terri Z Hisel,Ela B Plow,A M Barrett,Preeti Raghavan,Olga Boukrina,Fadi Nahab,Douglas D Gunzler,John Chae
    Source: Stroke
    CONCLUSIONS: By 6 months after 12 weeks of treatment, CCFES did not improve dexterity more than cNMES or TOT. CCFES reduced upper extremity impairment more than cNMES and TOT and improved upper limb function more than TOT.